title: Cost-benefit of stockpiling drugs for influenza pandemic.
abstract: We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
authors.affiliation: Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il
authors.forename: Ran D
authors.initials: RD
authors.lastname: Balicer
authors.forename: Michael
authors.initials: M
authors.lastname: Huerta
authors.forename: Nadav
authors.initials: N
authors.lastname: Davidovitch
authors.forename: Itamar
authors.initials: I
authors.lastname: Grotto
mesh_terms: D000081:Acetamides / Q000191:economics / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics*; D006801:Humans; D007223:Infant; D007251:Influenza, Human / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology*; D007557:Israel / Q000453:epidemiology; D008875:Middle Aged; D008954:Models, Biological; D018803:Models, Economic; D053139:Oseltamivir; D014944:World Health Organization
chemical_list: D000081:Acetamides; D000998:Antiviral Agents; D053139:Oseltamivir